[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Edward L. Cahill net worth and biography

Edward Cahill Biography and Net Worth

Director of Phreesia

Ed is a partner at HLM Venture Partners. Previously, he was a founding partner of Cahill, Warnock & Co. (now Camden Partners) and a managing director at Alex. Brown & Sons, where he headed the firm’s healthcare group. During his leadership at Alex. Brown & Sons, the firm underwrote public offerings or provided merger advisory services for over 200 healthcare companies and several leading biopharmaceutical companies. Ed is a director at Masimo Corp. and a trustee of Johns Hopkins Medicine, the Johns Hopkins Health System Corp. and Mercy Health Services.

What is Edward L. Cahill's net worth?: The estimated net worth of Edward L. Cahill is at least $1.31 million as of December 24th, 2020. Mr. Cahill owns 70,709 shares of Phreesia stock worth more than $1,310,238 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Cahill may own. Learn More about Edward L. Cahill's net worth.
How do I contact Edward L. Cahill?: The corporate mailing address for Mr. Cahill and other Phreesia executives is 432 Park Avenue South 12th Floor, New York NY, 10016. Phreesia can also be reached via phone at (888) 654-7473 and via email at [email protected]. Learn More on Edward L. Cahill's contact information.
Has Edward L. Cahill been buying or selling shares of Phreesia?: Edward L. Cahill has not been actively trading shares of Phreesia within the last three months. Learn More on Edward L. Cahill's trading history.
Who are Phreesia's active insiders?: Phreesia's insider roster includes Edward Cahill (Director), Allison Hoffman (General Counsel), Chaim Indig (CEO), David Linetsky (SVP), Gillian Munson (Director), Randy Rasmussen (CFO), Evan Roberts (COO), Amy Vanduyn (SVP), and Michael Weintraub (Director). Learn More on Phreesia's active insiders.
Are insiders buying or selling shares of Phreesia?: In the last twelve months, insiders at the sold shares 56 times. They sold a total of 151,985 shares worth more than $3,552,098.43. The most recent insider tranaction occured on October, 18th when SVP David Linetsky sold 1,100 shares worth more than $22,539.00. Insiders at Phreesia own 5.8% of the company. Learn More about insider trades at Phreesia.
Information on this page was last updated on 10/18/2024.

Edward L. Cahill Insider Trading History at Phreesia

Edward L. Cahill Buying and Selling Activity at Phreesia

Phreesia Company Overview

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.

Today's Range

Now: $18.65

$18.60

$18.66

50 Day Range

MA: $20.98

$18.04

$24.68

2 Week Range

Now: $18.65

$14.55

$29.16

Volume

3,978 shs

Average Volume

448,799 shs

Market Capitalization

$1.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94